Highest Analyst Upside Stocks
CORT is part of our highest analyst upside stock list, indicating analysts have a price target way above the current price.
CORCEPT THERAPEUTICS INC (CORT) Stock Price & Overview
NASDAQ:CORT • US2183521028
Current stock price
43.68 USD
+0.38 (+0.88%)
At close:
43.7276 USD
+0.05 (+0.11%)
After Hours:
The current stock price of CORT is 43.68 USD. Today CORT is up by 0.88%. In the past month the price increased by 35.74%. In the past year, price decreased by -29.82%.
CORT Key Statistics
52-Week Range28.6601 - 91
Current CORT stock price positioned within its 52-week range.
1-Month Range32.23 - 50.4
Current CORT stock price positioned within its 1-month range.
- Market Cap
- 4.646B
- P/E
- 53.27
- Fwd P/E
- 80.50
- EPS (TTM)
- 0.82
- Dividend Yield
- N/A
CORT Stock Performance
Today
+0.88%
1 Week
+4.77%
1 Month
+35.74%
3 Months
+25.77%
Longer-term
6 Months -44.49%
1 Year -29.82%
2 Years +87.31%
3 Years +93.87%
5 Years +91.66%
10 Years +815.72%
CORT Stock Chart
CORT Stock Screens
CORT currently appears in the following ChartMill screener lists.
CORT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CORT. When comparing the yearly performance of all stocks, CORT is a bad performer in the overall market: 73.38% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
CORT Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to CORT. Both the health and profitability get an excellent rating, making CORT a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CORT Earnings
On February 24, 2026 CORT reported an EPS of 0.2 and a revenue of 202.13M. The company missed EPS expectations (-34.64% surprise) and missed revenue expectations (-22.27% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.20
Revenue Reported202.125M
EPS Surprise -34.64%
Revenue Surprise -22.27%
CORT Forecast & Estimates
12 analysts have analysed CORT and the average price target is 68.75 USD. This implies a price increase of 57.39% is expected in the next year compared to the current price of 43.68.
For the next year, analysts expect an EPS growth of -33.82% and a revenue growth 15.59% for CORT
Analysts
Analysts78.33
Price Target68.75 (57.39%)
EPS Next Y-33.82%
Revenue Next Year15.59%
CORT Groups
Sector & Classification
CORT Financial Highlights
Over the last trailing twelve months CORT reported a non-GAAP Earnings per Share(EPS) of 0.82. The EPS decreased by -33.87% compared to the year before.
Income Statements
Revenue(TTM)761.41M
Net Income(TTM)99.65M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.09% | ||
| ROA | 11.91% | ||
| ROE | 15.38% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-23.08%
Sales Q2Q%11.12%
EPS 1Y (TTM)-33.87%
Revenue 1Y (TTM)12.79%
CORT Ownership
Ownership
Inst Owners72.81%
Shares106.37M
Float93.89M
Ins Owners6.65%
Short Float %13.26%
Short Ratio6.53
CORT Latest News, Press Relases and Analysis
7 days ago - By: Chartmill
CORT Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.38 | 878.257B | ||
| JNJ | JOHNSON & JOHNSON | 20.6 | 573.153B | ||
| MRK | MERCK & CO. INC. | 23.56 | 297.058B | ||
| PFE | PFIZER INC | 9.07 | 155.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.17 | 118.543B | ||
| ZTS | ZOETIS INC | 17.12 | 50.689B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.45 | 27.937B | ||
| VTRS | VIATRIS INC | 5.58 | 16.104B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 11.863B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.122B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.497B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.072B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CORT
Company Profile
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 730 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Company Info
IPO: 2004-04-15
CORCEPT THERAPEUTICS INC
101 Redwood Shores Parkway
Redwood City CALIFORNIA 94025 US
CEO: Joseph K. Belanoff
Employees: 730
Phone: 16506888803
CORCEPT THERAPEUTICS INC / CORT FAQ
What does CORCEPT THERAPEUTICS INC do?
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 730 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
What is the stock price of CORCEPT THERAPEUTICS INC today?
The current stock price of CORT is 43.68 USD. The price increased by 0.88% in the last trading session.
Does CORT stock pay dividends?
CORT does not pay a dividend.
How is the ChartMill rating for CORCEPT THERAPEUTICS INC?
CORT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists CORT stock?
CORT stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for CORCEPT THERAPEUTICS INC?
CORCEPT THERAPEUTICS INC (CORT) operates in the Health Care sector and the Pharmaceuticals industry.
Is CORCEPT THERAPEUTICS INC (CORT) expected to grow?
The Revenue of CORCEPT THERAPEUTICS INC (CORT) is expected to grow by 15.59% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.